Lupin aims for Japan top five, converting generics and offering Indian firms a way in
This article was originally published in Scrip
Executive Summary
India's Lupin expects to be among the top five to six generic companies in Japan by 2015, backed by a multi-faceted strategy that will include product introductions, shifting production to India to improve profitability, and an interest in brand buys, among others. Currently Lupin's Japanese subsidiary, Kyowa Pharmaceutical Industry Co, is the ninth largest generic pharmaceutical firm in Japan.